Considering that malignant tumors are prone to recurrence, the focus of this article was to explore whether PD-1 in CD8+ tumor-infiltrating lymphocytes are correlated with recurrence interval and progression-free survival (PFS). This evidence concerns the gene CD8A and neoplasm.